This webinar was originally held on November 2, 2023 and is now available for on demand viewing.
Duration: 1 hour
Already registered? Click here to log in.
Summary
A multidisciplinary conversation with views from the lab and Cardiology. Drs. Robert Christenson and James Januzzi will discuss the biology and value of BNP and NT-proBNP in heart failure diagnostics and therapeutic monitoring.
Speakers
Professor of Pathology Professor of Medical and Research Technology
University of Maryland School of Medicine
Dr. Christenson is professor of pathology and of medical and research technology at the University of Maryland School of Medicine in Baltimore. He heads the CCRL, a CLIA licensed and CAP accredited research lab specializing in government- and industry-sponsored clinical trials with an active program in cardiac and renal biomarkers. Clinically, he is medical director of Core Laboratories and point-of-care services at the University of Maryland Medical Center. With AACC, he served as chair of many committees and as the association’s president. Dr. Christenson has been very active in education and service worldwide. Dr. Christenson was bestowed AACC’s 2023 Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine and the IFCC’s 2023 Henry-Wishinsky Award for Distinguished International Service. He is currently Editor-in-Chief of the Journal of Applied Laboratory Medicine.
Cardiologist and Director, Dennis and Marilyn Barry Fellowship in Cardiology Research
Massachusetts General Hospital
Dr. James Januzzi is the Hutter Family Professor of Medicine at Harvard Medical School, Director of the Guideline Directed Medical Therapy Clinic at Massachusetts General Hospital, and Director of Heart Failure and Biomarker Trials at the Baim Institute for Clinical Research. He is a Trustee of the American College of Cardiology and an Editor at the Journal of the American College of Cardiology. Dr. Januzzi has spent his career focusing on the role of biomarker testing for optimizing diagnosis and treatment of various disease states, notably including recognition and treatment of heart failure. His work has set international standards for use of natriuretic peptides, troponins, and other biomarkers and his research is featured in clinical practice guidelines and consensus documents for patient care.
Sponsored by:
